Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Published

Journal Article

Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32,400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 microg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac alpha-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.

Full Text

Duke Authors

Cited Authors

  • Lippman, SM; Goodman, PJ; Klein, EA; Parnes, HL; Thompson, IM; Kristal, AR; Santella, RM; Probstfield, JL; Moinpour, CM; Albanes, D; Taylor, PR; Minasian, LM; Hoque, A; Thomas, SM; Crowley, JJ; Gaziano, JM; Stanford, JL; Cook, ED; Fleshner, NE; Lieber, MM; Walther, PJ; Khuri, FR; Karp, DD; Schwartz, GG; Ford, LG; Coltman, CA

Published Date

  • January 19, 2005

Published In

Volume / Issue

  • 97 / 2

Start / End Page

  • 94 - 102

PubMed ID

  • 15657339

Pubmed Central ID

  • 15657339

Electronic International Standard Serial Number (EISSN)

  • 1460-2105

Digital Object Identifier (DOI)

  • 10.1093/jnci/dji009

Language

  • eng

Conference Location

  • United States